Immune checkpoint inhibitor (ICI) is currently emerged as one of the most promising approaches to treat cancer, but it is still largely refractory to numerous patients.[50] PD‐L1 antibody immunotherapy can indeed relieve the inhibition of CD8+ T cells, thereby releasing GZMB and cytokines (such as IFNγ and TNFα) to kill tumor cells. Here, IFNG is linked to cancer.